Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Radiopharmaceutical development for diagnostic and therapeutic applications

Conference ·
OSTI ID:6964769
Several radioisotopes are currently being evaluated for radiopharmaceutical development. These include the radioisotopes of iodine for developmental, therapeutic and diagnostic applications by SPECT. Other metallic radioisotopes are being developed for diagnostic and therapeutic applications. All these radioisotopes (copper-64, osmium-191, and tungsten-188) are HFIR produced, except yttrium-90, which is a by-product of uranium fission. Osmium-191 decays by isomeric transition to iridium-191m (half-life 5 sec). A bed-side Os/Ir generator has been developed which allows bolus elution of pure iridium-191m for first-pass heart studies in adults and children. Potential use of radiolabeled nucleosides as tumor localization agents is also addressed. The utility of nucleosides coupled with tumor specific antibodies for improved selectivity in immunotherapy and diagnosis of tumor should be explored. New production and purification techniques for medical radioisotopes and new versatile agents for radiolabeling antibodies for wide-spread applications should be investigated.
Research Organization:
Oak Ridge National Lab., TN (USA)
DOE Contract Number:
AC05-84OR21400
OSTI ID:
6964769
Report Number(s):
CONF-8610204-1; ON: DE87002624
Country of Publication:
United States
Language:
English

Similar Records

Rhenium-188 Labeled Radiopharmaceuticals: Current Clinical Applications in Oncology and Promising Perspectives
Journal Article · Thu Jun 13 20:00:00 EDT 2019 · Frontiers in Medicine · OSTI ID:1628049

New osmium-191. -->. iridium-191m generator
Journal Article · Sun Nov 30 23:00:00 EST 1980 · J. Nucl. Med.; (United States) · OSTI ID:6667523

Rhenium Radioisotopes for Therapeutic Radiopharmaceutical Development
Conference · Sun Jan 17 23:00:00 EST 1999 · OSTI ID:6245